🚀
Enjoy a 7-Day Free Trial Thru May 01, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Athira Pharma Inc (NAS:ATHA)
News
Athira Pharma Inc
NAS
:ATHA (USA) Â
Ordinary Shares
$ 2.03
-0.05 (-2.39%)
10:09 PM EST
P/E:
At Loss
P/B:
0.60
Market Cap:
$ 77.80M
Enterprise V:
$ -66.11M
Volume:
83.59K
Avg Vol (2M):
405.17K
Warning! GuruFocus detected 2 Severe warning signs with ATHA.
Try a 7-Day Free Trial
to check it out.
Volume:
83.59K
Market Cap $:
77.80M
PE Ratio:
At Loss
Avg Vol (2M):
405.17K
Enterprise Value $:
-66.11M
PB Ratio:
0.60
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Athira Pharma Inc (NAS:ATHA) Stock News, Headlines & Updates
Athira Pharma Inc Stock News from GuruFocus
Total 191
1
2
3
4
5
Apr 15, 2024
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Marketwired
•
6:00am
Apr 11, 2024
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
Marketwired
•
6:00am
Feb 06, 2024
Athira Pharma Inc at Jefferies CNS & Neuro Summit Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc at Goldman Sachs Healthcare Conference Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc Annual Shareholders Meeting Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc at JMP Securities Life Sciences Conference Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc at Stifel CNS Days (Virtual) Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc at Needham Neuroscience Forum (Virtual) Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc at Stifel Healthcare Conference Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc To Discuss The ACT-AD Results Transcript
GuruFocus Research
•
9:36pm
Athira Pharma Inc at Stifel CNS Days (Virtual) Transcript
GuruFocus Research
•
9:35pm
Q4 2021 Athira Pharma Inc Earnings Call Transcript
GuruFocus Research
•
9:35pm
Oct 05, 2023
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Marketwired
•
4:00pm
Sep 28, 2023
Athira Pharma to Participate in Upcoming October Conferences
Marketwired
•
6:00am
Sep 19, 2023
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Marketwired
•
6:00am
Aug 10, 2023
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
Marketwired
•
4:00pm
Jul 17, 2023
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease
Marketwired
•
6:00am
Jul 06, 2023
Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023
Marketwired
•
6:00am
Feb 01, 2023
Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
Stock market mentor
•
6:00am
Jan 31, 2023
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
Stock market mentor
•
6:00am
Dec 21, 2022
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
Tiesvg
•
6:00am
Dec 13, 2022
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Athira Pharma, Inc. (NASDAQ: ATHA) and Encourages Long-Term ATHA Investors to Contact the Firm
Value_Insider
•
8:00pm
Dec 05, 2022
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Value_Insider
•
7:00am
Dec 01, 2022
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
Value_Insider
•
6:00am
Nov 29, 2022
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
Value_Insider
•
10:00am
Nov 28, 2022
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Value_Insider
•
6:00am
Nov 09, 2022
Athira Pharma to Present at Stifel 2022 Healthcare Conference
Value_Insider
•
6:00am
Nov 07, 2022
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
Value_Insider
•
6:00am
Oct 17, 2022
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis
Value_Insider
•
6:00am
Oct 16, 2022
INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Athira Pharma, Inc. (NASDAQ: ATHA) and Encourages Long-Term ATHA Investors to Contact the Firm
Value_Insider
•
4:00pm
Aug 03, 2022
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022
PurpleRose
•
11:00am
Aug 02, 2022
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
PurpleRose
•
3:00pm
Jul 25, 2022
SILVERARC CAPITAL MANAGEMENT, LLC Buys 2, Sells 3 in 2nd Quarter
GuruFocus Research
•
5:00pm
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer's Association International Conference 2022
PurpleRose
•
6:00am
Jul 12, 2022
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
PurpleRose
•
6:30am
Jul 10, 2022
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
PurpleRose
•
5:06pm
Jul 02, 2022
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
GuruFocusNews
•
6:29am
Jun 30, 2022
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
GuruFocusNews
•
5:06pm
Jun 22, 2022
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
GuruFocusNews
•
6:26am
Total 191
1
2
3
4
5
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news